Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. (1/1571)

-The clinical efficacy of anthracycline antineoplastic agents is limited by a high incidence of severe and usually irreversible cardiac toxicity, the cause of which remains controversial. In primary cultures of neonatal and adult rat ventricular myocytes, we found that daunorubicin, at concentrations /=10 micromol/L induced necrotic cell death within 24 hours, with no changes characteristic of apoptosis. To determine whether reactive oxygen species play a role in daunorubicin-mediated apoptosis, we monitored the generation of hydrogen peroxide with dichlorofluorescein (DCF). However, daunorubicin (1 micromol/L) did not increase DCF fluorescence, nor were the antioxidants N-acetylcysteine or the combination of alpha-tocopherol and ascorbic acid able to prevent apoptosis. In contrast, dexrazoxane (10 micromol/L), known clinically to limit anthracycline cardiac toxicity, prevented daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations (>/=10 micromol/L). The antiapoptotic action of dexrazoxane was mimicked by the superoxide-dismutase mimetic porphyrin manganese(II/III)tetrakis(1-methyl-4-peridyl)porphyrin (50 micromol/L). The recognition that anthracycline-induced cardiac myocyte apoptosis, perhaps mediated by superoxide anion generation, occurs at concentrations well below those that result in myocyte necrosis, may aid in the design of new therapeutic strategies to limit the toxicity of these drugs.  (+info)

Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. (2/1571)

The site of action of 3-(2,2,2-trimethylhydrazinium) propionate (THP), a new cardioprotective agent, was investigated in mice and rats. I.p. administration of THP decreased the concentrations of free carnitine and long-chain acylcarnitine in heart tissue. In isolated myocytes, THP inhibited free carnitine transport with a Ki of 1340 microM, which is considerably higher than the observed serum concentration of THP. The major cause of the decreased free carnitine concentration in heart was found to be the decreased serum concentration of free carnitine that resulted from the increased renal clearance of carnitine by THP. The estimated Ki of THP for inhibiting the reabsorption of free carnitine in kidneys was 52.2 microM, which is consistent with the serum THP concentration range. No inhibition of THP on the carnitine palmitoyltransferase activity in isolated mitochondrial fractions was observed. These results indicate that the principal site of action of THP as a cardioprotective agent is the carnitine transport carrier in the kidney, but not the carrier in the heart.  (+info)

Treatment patterns for heart failure in a primary care environment. (3/1571)

Little published information regarding current pharmacotherapeutic treatment patterns for congestive heart failure (CHF) in nonacademic, ambulatory care settings is available. We sought to assess, in a nonacademic primary care environment, pharmacotherapeutic treatment patterns for CHF with respect to consistency with clinical trial evidence and published treatment guideline recommendations. Over an 18-month period, we examined CHF pharmacotherapy using a computerized, integrated clinical diagnoses and prescription database from an outpatient community healthcare center without academic affiliations. We identified adult patients meeting contact criteria and with diagnosis of CHF by International Classification of Diseases (ICD-9-CM) coding and assessed prescribed therapy as well as select comorbid conditions. Drugs of interest included those with known or suspected benefit or detriment and those with unproven benefit. An eligible group of 14,983 patients was identified, from which a cohort of 148 patients with CHF was selected. Forty-one percent of these 148 patients were prescribed an angiotensin converting enzyme (ACE) inhibitor, 34% digoxin, 12% diuretic, 12% hydralazine + nitrate, 20% inhaled beta-agonists, and 66% warfarin. Only 5% of patients were prescribed the combination of an ACE inhibitor, digoxin, and diuretic. Thirty-one percent had a comorbid diagnosis of atrial fibrillation, of whom 44% were prescribed digoxin, 22% diltiazem, 15% beta-blockers, 15% digoxin and diltiazem, 7% digoxin and a beta-blocker, and 33% warfarin. In general, recommended therapies for CHF appeared underutilized in this cohort, whereas those of unclear benefit and potential detriment appeared overutilized. Although these results may not be readily generalized to the entire healthcare system, they do suggest a need for additional analysis and potential intervention.  (+info)

Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ. (4/1571)

For the further elucidation of the central functions of nociceptin/orphanin FQ (noc/OFQ), the endogenous ligand of the G protein-coupled opioid receptor-like receptor ORL1, centrally acting specific antagonists will be most helpful. In this study it was found that the hexapeptide acetyl-RYYRIK-NH2 (Ac-RYYRIK-NH2), described in literature as partial agonist on ORL1 transfected in CHO cells, antagonizes the stimulation of [35S]-GTPgammaS binding to G proteins by noc/OFQ in membranes and sections of rat brain. The antagonism of the peptide was competitive, of high affinity (Schild constant 6.58 nM), and specific for noc/OFQ in that the stimulation of GTP binding by agonists for the mu-, delta-, and kappa-opioid receptor was not inhibited. The hexapeptide also fully inhibited the chronotropic effect of noc/OFQ on neonatal rat cardiomyocytes. It is suggested that Ac-RYYRIK-NH2 may provide a promising starting point for in vivo tests for antagonism of the action of noc/OFQ and for the further development of highly active and specific antagonists.  (+info)

Acute anti-ischemic effect of testosterone in men with coronary artery disease. (5/1571)

BACKGROUND: The role of testosterone on the development of coronary artery disease in men is controversial. The evidence that men have a greater incidence of coronary artery disease than women of a similar age suggests a possible causal role of testosterone. Conversely, recent studies have shown that the hormone improves endothelium-dependent relaxation of coronary arteries in men. Accordingly, the aim of the present study was to evaluate the effect of acute administration of testosterone on exercise-induced myocardial ischemia in men. METHODS AND RESULTS: After withdrawal of antianginal therapy, 14 men (mean age, 58+/-4 years) with coronary artery disease underwent 3 exercise tests according to the modified Bruce protocol on 3 different days (baseline and either testosterone or placebo given in a random order). The exercise tests were performed 30 minutes after administration of testosterone (2.5 mg IV in 5 minutes) or placebo. All patients showed at least 1-mm ST-segment depression during the baseline exercise test and after placebo, whereas only 10 patients had a positive exercise test after testosterone. Chest pain during exercise was reported by 12 patients during baseline and placebo exercise tests and by 8 patients after testosterone. Compared with placebo, testosterone increased time to 1-mm ST-segment depression (579+/-204 versus 471+/-210 seconds; P<0. 01) and total exercise time (631+/-180 versus 541+/-204 seconds; P<0. 01). Testosterone significantly increased heart rate at the onset of 1-mm ST-segment depression (135+/-12 versus 123+/-14 bpm; P<0.01) and at peak exercise (140+/-12 versus 132+/-12 bpm; P<0.01) and the rate-pressure product at the onset of 1-mm ST-segment depression (24 213+/-3750 versus 21 619+/-3542 mm Hgxbpm; P<0.05) and at peak exercise (26 746+/-3109 versus 22 527+/-5443 mm Hgxbpm; P<0.05). CONCLUSIONS: Short-term administration of testosterone induces a beneficial effect on exercise-induced myocardial ischemia in men with coronary artery disease. This effect may be related to a direct coronary-relaxing effect.  (+info)

Drug-induced heart failure. (6/1571)

Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders such as coronary heart disease and hypertension. However, several classes of drugs may induce heart failure in patients without concurrent cardiovascular disease or may precipitate the occurrence of heart failure in patients with preexisting left ventricular impairment. We reviewed the literature on drug-induced heart failure, using the MEDLINE database and lateral references. Successively, we discuss the potential role in the occurrence of heart failure of cytostatics, immunomodulating drugs, antidepressants, calcium channel blocking agents, nonsteroidal anti-inflammatory drugs, antiarrhythmics, beta-adrenoceptor blocking agents, anesthetics and some miscellaneous agents. Drug-induced heart failure may play a role in only a minority of the patients presenting with heart failure. Nevertheless, drug-induced heart failure should be regarded as a potentially preventable cause of heart failure, although sometimes other priorities do not offer therapeutic alternatives (e.g., anthracycline-induced cardiomyopathy). The awareness of clinicians of potential adverse effects on cardiac performance by several classes of drugs, particularly in patients with preexisting ventricular dysfunction, may contribute to timely diagnosis and prevention of drug-induced heart failure.  (+info)

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. (7/1571)

1. We investigated the cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor mice. The in vitro pharmacology of these agonists was determined at recombinant (human) alpha2-adrenoceptors and at endogenous (dog) alpha2A-adrenoceptors. 2. In wild-type mice, rilmenidine, moxonidine (100, 300 and 1000 microg kg(-1), i.v.) and clonidine (30, 100 and 300 microg kg(-1), i.v.) dose-dependently decreased blood pressure and heart rate. 3. In D79N alpha2A-adrenoceptor mice, responses to rilmenidine and moxonidine did not differ from vehicle control. Clonidine-induced hypotension was absent, but dose-dependent hypertension and bradycardia were observed. 4. In wild-type mice, responses to moxonidine (1 mg kg(-1), i.v.) were antagonized by the non-selective, non-imidazoline alpha2-adrenoceptor antagonist, RS-79948-197 (1 mg kg(-1), i.v.). 5. Affinity estimates (pKi) at human alpha2A-, alpha2B- and alpha2C-adrenoceptors, respectively, were: rilmenidine (5.80, 5.76 and 5.33), moxonidine (5.37, <5 and <5) and clonidine (7.21, 7.16 and 6.87). In a [35S]-GTPgammaS incorporation assay, moxonidine and clonidine were alpha2A-adrenoceptor agonists (pEC50/intrinsic activity relative to noradrenaline): moxonidine (5.74/0.85) and clonidine (7.57/0.32). 6. In dog saphenous vein, concentration-dependent contractions were observed (pEC50/intrinsic activity relative to noradrenaline): rilmenidine (5.83/0.70), moxonidine (6.48/0.98) and clonidine (7.22/0.83). Agonist-independent affinities were obtained with RS-79948-197. 7. Thus, expression of alpha2A-adrenoceptors is a prerequisite for the cardiovascular effects of moxonidine and rilmenidine in conscious mice. There was no evidence of I1-imidazoline receptor-mediated effects. The ability of these compounds to act as alpha2A-adrenoceptor agonists in vitro supports this conclusion.  (+info)

Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. (8/1571)

We investigated effects of a novel cardioprotective drug, JTV-519 (4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahy dro-1,4-benzothiazepine monohydrochloride) on membrane currents of guinea pig ventricular myocytes by whole-cell voltage and current clamp methods. The fast Na+ current (iNa) was activated by ramp pulses from various holding potentials of -90, -80 or -60 mV to 10 mV with various intervals. At 0.2 Hz, JTV-519 inhibited iNa in a concentration-dependent manner with an IC50 of approximately 1.2 and 2 microM at the holding potential of -60 and -90 mM, respectively, implicating a voltage-dependent block. Increasing the pulse frequency from 1 to 2 or 3.3 Hz in the presence of 1 microM JTV-519 shortened the time-course and increased the level of iNa block, indicating a frequency-dependent block. The time-course of iNa blocking by JTV-519 was slower than that of lidocaine and similar to that of quinidine. Ca2+ current (iCa) and the inwardly rectifying K+ current (iK1) were also inhibited by JTV-519. JTV-519 decreased the duration and the height of the plateau of the action potential. We conclude that JTV-519 has frequency- and voltage-dependent blocking effects on iNa as well as inhibition of iCa and iK1.  (+info)

Cardiovascular agents are a class of medications that are used to treat various conditions related to the cardiovascular system, which includes the heart and blood vessels. These agents can be further divided into several subcategories based on their specific mechanisms of action and therapeutic effects. Here are some examples:

1. Antiarrhythmics: These drugs are used to treat abnormal heart rhythms or arrhythmias. They work by stabilizing the electrical activity of the heart and preventing irregular impulses from spreading through the heart muscle.
2. Antihypertensives: These medications are used to lower high blood pressure, also known as hypertension. There are several classes of antihypertensive drugs, including diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors.
3. Anticoagulants: These drugs are used to prevent blood clots from forming or growing larger. They work by interfering with the coagulation cascade, which is a series of chemical reactions that lead to the formation of a blood clot.
4. Antiplatelet agents: These medications are used to prevent platelets in the blood from sticking together and forming clots. They work by inhibiting the aggregation of platelets, which are small cells in the blood that help form clots.
5. Lipid-lowering agents: These drugs are used to lower cholesterol and other fats in the blood. They work by reducing the production or absorption of cholesterol in the body or increasing the removal of cholesterol from the bloodstream. Examples include statins, bile acid sequestrants, and PCSK9 inhibitors.
6. Vasodilators: These medications are used to widen blood vessels and improve blood flow. They work by relaxing the smooth muscle in the walls of blood vessels, causing them to dilate or widen. Examples include nitrates, calcium channel blockers, and ACE inhibitors.
7. Inotropes: These drugs are used to increase the force of heart contractions. They work by increasing the sensitivity of heart muscle cells to calcium ions, which are necessary for muscle contraction.

These are just a few examples of cardiovascular medications that are used to treat various conditions related to the heart and blood vessels. It is important to note that these medications can have side effects and should be taken under the guidance of a healthcare provider.

Fekjær, Hans Olav (December 2013). "Alcohol-a universal preventive agent? A critical analysis". Addiction. 108 (12): 2051-2057 ... Some early reviews showed that light alcohol consumption may have a protective effect on cardiovascular health. For instance, a ... Some studies have suggested that one drink per day may have cardiovascular benefits. However, these studies are controversial, ... However, the researchers warned against encouraging cardiovascular patients who do not regularly consume alcohol to start ...
Berne RM (January 1993). "Adenosine--a cardioprotective and therapeutic agent". Cardiovascular Research. 27 (1): 2. doi:10.1093 ...
A Promising KATP Channel Activating Agent". Cardiovascular Drug Reviews. 18: 25. doi:10.1111/j.1527-3466.2000.tb00031.x. v t e ...
Agents. 11 (3): 104-10. PMID 9498159. Tousoulis, Dimitris; Stefanadis, Christodoulos (2013-07-29). Biomarkers in Cardiovascular ... patients with a previous cardiovascular event - benefited from the treatment. These people were 39% less likely to die or be ...
Damato, Anthony N. (1 July 1969). "Diphenylhydantoin: Pharmacological and clinical use". Progress in Cardiovascular Diseases. ... Class II agents are anti-sympathetic nervous system agents. Most agents in this class are beta blockers. Class III agents ... Class IV agents affect calcium channels and the AV node. Class V agents work by other or unknown mechanisms. With regard to ... Class I agents are called membrane-stabilizing agents, "stabilizing" referring to the decrease of excitogenicity of the plasma ...
"Agents Used in Dyslipidemia , Basic & Clinical Pharmacology, 15e , AccessPharmacy , McGraw-Hill Medical". accesspharmacy. ... Almeida, Shone O.; Budoff, Matthew (November 2019). "Effect of statins on atherosclerotic plaque". Trends in Cardiovascular ... such as analgesics and topical agents. Two diseases from the top 10 causes of death introduced by the World Health Organization ... WHO) in 2019 are used as examples, namely ischemic heart disease (ranked 1st) from cardiovascular diseases and Chronic ...
82-. ISBN 978-0-8493-4724-5. Dennis V. Cokkinos (6 November 2014). Introduction to Translational Cardiovascular Research. ... Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. ...
Syed YY (August 2016). "Idarucizumab: A Review as a Reversal Agent for Dabigatran". American Journal of Cardiovascular Drugs. ... Cardiovascular Quality and Outcomes. 9 (2): 126-134. doi:10.1161/CIRCOUTCOMES.115.002369. PMID 26812933. S2CID 6840541. Kiser K ... and mucosal protective agent. In severe bleeding, measures include discontinuation of dabigatran immediately, and ... the use of specific reversal agents such as idarucizumab for dabigatran, and emergency endoscopic management. A small but ...
Head, G.; Mayorov, D. (1 January 2006). "Imidazoline Receptors, Novel Agents and Therapeutic Potential". Cardiovascular & ... novel agents and therapeutic potential". Cardiovasc Hematol Agents Med Chem. 4 (1): 17-32. doi:10.2174/187152506775268758. PMID ... Bousquet, P (November 2001). "I1 receptors, cardiovascular function, and metabolism". American Journal of Hypertension. 14 (11 ... alkylating agent, inactivates I2 receptors) Efaroxan (I1, α2 adrenoceptor antagonist) Idazoxan (I1, I2 antagonist, α2 ...
Cardiovascular & Hematological Agents. 3 (3): 203-19. doi:10.2174/1568016054368188. PMID 15974885. Amsterdam EA, Wenger NK, ... Agents and Actions. Supplements. 15: 199-212. PMID 6385647. "Ticlopidine". Drug Information Portal. U.S. National Library of ...
Cardiovascular & Hematological Agents in Medicinal Chemistry. 7 (1): 82-90. doi:10.2174/187152509787047676. PMID 19149547. ... Jacoby GA, Tran J (July 1999). "Sequence of the MIR-1 beta-lactamase gene". Antimicrobial Agents and Chemotherapy. 43 (7): 1759 ... Since the tumor results from undifferentiated cells, agents that promote differentiation hold promise as possible therapies. A ... Cardiovascular Research. 84 (3): 434-41. doi:10.1093/cvr/cvp232. PMID 19581315. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi ...
Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be ... In the same study, no reduction in the rate of cardiovascular events (including death) was shown. In one study of people ... April 2010). "Effect of valsartan on the incidence of diabetes and cardiovascular events". The New England Journal of Medicine ... Khalil P, Kabbach G, Said S, Mukherjee D (2018). "Entresto, a New Panacea for Heart Failure?". Cardiovascular & Hematological ...
Yeung J, Holinstat M (July 2011). "12-lipoxygenase: a potential target for novel anti-platelet therapeutics". Cardiovascular & ... HETE metabolic pathway has dual functions in promoting or inhibiting platelet responses depending on the stimulating agent and ... Hematological Agents in Medicinal Chemistry. 9 (3): 154-64. doi:10.2174/187152511797037619. PMC 3171607. PMID 21838667. ...
Cardiovascular & Hematological Agents in Medicinal Chemistry. 11 (1): 14-24. doi:10.2174/1871525711311010005. ISSN 1871-5257. ...
Most agents of this class are guanidinium compounds and have little capacity to cross the blood-brain barrier. Lukas G (1973 ... Hypertensive Cardiovascular Disease: Pathophysiology and Treatment. Springer Netherlands. pp. 828-833. doi:10.1007/978-94-009- ... Examples of these agents include bethanidine, bretylium, debrisoquine, guanadrel, guanazodine, guancydine, guanethidine, ... Stokes, Gordon S.; Oates, Helen F. (1982). "Blockers of the Neuromuscular Junction as Antihypertensive Agents". ...
"Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents". Journal of ... Cardiovascular Pharmacotherapeutics. Cardiotext Publishing. 2011. pp. 251-52. ISBN 978-1935395621. Retrieved 28 December 2018. ... Grossman E, Messerli FH (2004). "Calcium antagonists". Progress in Cardiovascular Diseases. 47 (1): 34-57. doi:10.1016/j.pcad. ... Peroutka SJ (November 1983). "The pharmacology of calcium channel antagonists: a novel class of anti-migraine agents?". ...
... though useful inotropic agent". Recent Patents on Cardiovascular Drug Discovery. 5 (1): 66-68. doi:10.2174/157489010790192593. ... It is not an α-adrenergic agonist, does not cause vasoconstriction, and is not a pressor agent. As of 2004 there was some ... Use in sepsis has been explored in clinical trials, but use of an inotropic agent like dobutamine or dopexamine did not reduce ... Dopexamine is used in hospitals as an inotropic agent to reduce exacerbations of heart failure and to treat heart failure ...
The drug is a potential first-in-class agent for prevention of reperfusion injury in CABG surgery. Schering began patient ... Cardiovascular Research. 28 (3): 379-83. doi:10.1093/cvr/28.3.379. PMID 8174159. Russell RR, Bergeron R, Shulman GI, Young LH ( ... Acadesine is an adenosine regulating agent developed by PeriCor Therapeutics and licensed to Schering-Plough in 2007 for phase ... Mullane K (January 1993). "Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury". ...
Yakhontov LN, Liberman SS (March 1987). "Agents for the treatment of cardiovascular diseases". Pharmaceutical Chemistry Journal ...
A Potential Cardiovascular Protective Agent". Frontiers in Pharmacology. 7: 362. doi:10.3389/fphar.2016.00362. ISSN 1663-9812. ... "Synthesis and Cytotoxicity Evaluation of 13-n-Alkyl Berberine and Palmatine Analogues as Anticancer Agents". Molecules. 17 (10 ...
"Cardiovascular Pathology Index Images". The Internet Pathology Laboratory for Medical Education. Florida State University ... Brook I (April 2009). "Pericarditis caused by anaerobic bacteria". International Journal of Antimicrobial Agents. 33 (4): 297- ... Cardiovascular Imaging. 17 (6): 707. doi:10.1093/ehjci/jew056. PMID 27044912. Atallah PC, Kassier A, Powers S (September 2014 ... Cardiovascular Medicine. p. 64. ISBN 978-1-934465-28-8. Archived from the original on 2010-08-02. "Pericarditis". National ...
Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Hoboken, N.J.: Wiley. ISBN 9780471270904. "Merck's Plendil ( ...
Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Wiley. pp. 55-154. ISBN 978-0471370291. "Triamterene and ... Fink CA, McKenna JM, Werner LH (2003). "Diuretic and Uricosuric Agents". In Abraham DJ (ed.). Burger's medicinal chemistry and ... Crosley AP, Ronquillo LM, Strickland WH, Alexander F (February 1962). "Triamterene, a new natruretic agent. Preliminary ... French launched it as a single agent under the brand Dyrenium in 1964.: 83 The combination drug with hydrochlorothiazide, ...
Other reversal agents for antithrombotic drugs Andexanet alfa Ciraparantag Vitamin K Idarucizumab "Specialist Pharmacy Service ... "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular ... is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent ...
Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for ... Recent Patents on Cardiovascular Drug Discovery. 6 (1): 16-19. doi:10.2174/157489011794578473. ...
Jia, Sujie; Hu, Changping (2010). "Pharmacological effects of rutaecarpine as a cardiovascular protective agent". Molecules. 15 ... rutecarpine does not appear to cause negative effects on the cardiovascular system; in fact, it compensates for[clarification ...
Mathur PP (December 1972). "Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate". American Heart ... It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic ... Disopyramide does not act as a blocking agent for beta or alpha adrenergic receptors, but does have a significant negative ... These concerns about the drug must be viewed from the clinical perspective that disopyramide is generally the last agent that ...
The symptoms of norbormide were very similar to the better known Ca2+ entry blocker agents. Therefore, norbormide is not only ... Another study has shown that there were respiratory depressions after the cardiovascular effects in the rats which were treated ... "Norbormide - a Rattus-specific toxic agent". J. Forensic Sci. 1965: 80-83. (CS1: long volume value, Chemical articles with ... Yelnosky J, Lawlor R (September 1971). "Cardiovascular effects of norbormide". European Journal of Pharmacology. 16 (1): 117-9 ...
Bristol JA (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. p. 111. ISBN 978-0-471-09228-5. Drug Metabolism ... Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science ...
April 2010). "Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be ... Many conventional cardiovascular risk factors have been independently linked to whole blood viscosity. Anemia can reduce blood ... With the development of cardiovascular prosthetic devices such as heart valves and blood pumps, the understanding of pulsating ... These functions of the cardiovascular system are directly related to vascular resistance, preload, afterload, and perfusion, ...
Anticoagulants, Cardiovascular. Class Summary. These agents prevent recurrent or ongoing thromboembolic occlusion. ... Diuretic Agents. Class Summary. Diuretics can be useful to reduce the amount of ascites, providing symptomatic relief and ... Antifibrinolytic Agents. Class Summary. Fibrinolytic drugs are used to dissolve a pathologic intraluminal thrombus or embolus ... This agent is often preferred because of its potassium-sparing effects, particularly in a clinical setting that includes ...
Pharmacological Actions : Anticholesteremic Agents, Antihypertensive Agents, Cardiovascular Agents, Hypoglycemic Agents. ... Pharmacological Actions : Anti-Inflammatory Agents, Antioxidants, Cardiovascular Agents, Neuroprotective Agents. Additional ... Pharmacological Actions : Antihypertensive Agents, Antioxidants, Cardiovascular Agents, Cytoprotective, Vasodilator Agents. ... Pharmacological Actions : Anti-Fibrotic, Anti-Inflammatory Agents, Cardioprotective, Cardiovascular Agents, Hypoglycemic Agents ...
Eisais news release CARDIOVASCULAR OUTCOMES TRIAL OF ANTI-OBESITY AGENT LORCASERIN TO CONTINUE BASED ON RECOMMENDATION OF ... CARDIOVASCULAR OUTCOMES TRIAL OF ANTI-OBESITY AGENT LORCASERIN TO CONTINUE BASED ON RECOMMENDATION OF INDEPENDENT DATA ... CARDIOVASCULAR OUTCOMES TRIAL OF ANTI-OBESITY AGENT LORCASERIN TO CONTINUE BASED ON RECOMMENDATION OF INDEPENDENT DATA ... 2.About Cardiovascular Outcomes Trials, CAMELLIA-TIMI61 Study. The CAMELLIA (Cardiovascular And Metabolic Effects of Lorcaserin ...
The commentary on the trial by Marso et al1 assessing the cardiovascular (CV) safety of a new agent for treating type 2 ... Estimation of the cardiovascular events required to fall below the FDA target cut-off in the design of a cardiovascular safety ... Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for ... Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for ...
Cardiovascular signs *Atrioventricular block and cardiac arrest (with high-dose exposure) *Hypotension (with high-dose exposure ... Nerve agentsplus icon *Case Definition: Nerve Agents or Organophosphates. *Toxic Syndrome Description: Nerve Agent and ... Riot control agents/tear gasplus icon *Facts About Riot Control Agents ... Vesicants, also referred to as "blister agents," were the most commonly used chemical warfare agents during World War I. The ...
Psychotropic agents demand close attention in the perioperative period. Their complex effects on cardiovascular and autonomic ... Co-Director of the Cardiovascular Institute, Director of Cardiovascular and Thoracic Surgery, Baylor Scott & White Health. ... These agents may be used for the allergic patient or in preparing a patient for exposure to an allergenic trigger, such as ... Many different agents have been used to alter gastric volume and increase the pH of gastric fluid. Anticholinergics, H2 ...
Cardiovascular agents. Class Summary. These agents are the drugs of choice. They may be useful in reducing pain and ulceration. ...
Psychotropic agents demand close attention in the perioperative period. Their complex effects on cardiovascular and autonomic ... Co-Director of the Cardiovascular Institute, Director of Cardiovascular and Thoracic Surgery, Baylor Scott & White Health. ... These agents may be used for the allergic patient or in preparing a patient for exposure to an allergenic trigger, such as ... Many different agents have been used to alter gastric volume and increase the pH of gastric fluid. Anticholinergics, H2 ...
Death may occur within 24 to 48 hours due to complete cardiovascular collapse. ... Your Incident Commander will provide you with decontaminants specific for the agent released or the agent believed to have been ... They also use it as a smoke agent, because it produces clouds of irritating white smoke. It has a match-like or garlic-like, ... Agents can seep into the crevices of equipment making it dangerous to handle. The following methods can help decontaminate ...
It is the least volatile nerve agent. Table 1 lists selected physical properties for each of the nerve agents. ... G-type agents are clear,colorless, and tasteless liquids that are miscible in water and most organic solvents. GB is odorless ... and is the most volatile nerve agent; however, it evaporates at about the same rate as water. GA has a slightly fruity odor, ... Nerve agents are the most toxic of the known chemical warfare agents. They are chemically similar to organophosphate pesticides ...
Cardiovascular signs *Atrioventricular block and cardiac arrest (with high-dose exposure) *Hypotension (with high-dose exposure ... Nerve agentsplus icon *Case Definition: Nerve Agents or Organophosphates. *Toxic Syndrome Description: Nerve Agent and ... Riot control agents/tear gasplus icon *Facts About Riot Control Agents ... Vesicants, also referred to as "blister agents," were the most commonly used chemical warfare agents during World War I. The ...
Cardiovascular. 2.9 (1.5 to 5.7). 0.002. Infectious. Coexisting conditions. Diabetes mellitus. 2.1 (1.5 to 3.1). ,0.001. ... Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus Yehuda Carmeli*†. ... Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus. ...
Horizons in World Cardiovascular Research. Volume 15. $290.00. Select options. * Cardiotoxicity of Chemotherapeutic Agents. $ ... Horizons in World Cardiovascular Research. Volume 13. $290.00. Select options. * Everything You Need to Know: Out of the ... Horizons in World Cardiovascular Research. Volume 14. $290.00. Select options. * Heart Failure: What a Non-Heart Failure ... Horizons in World Cardiovascular Research. Volume 12. $290.00. Select options. * Sudden Cardiac Death: Predictors, Prevalence ...
Pharmacokinetics of cardiovascular, central nervous system, and antimicrobial drugs / Peter G. Welling, Francis L. S. Tse. by ...
Cardiovascular Agents. ➢ Cardiovascular agents (drugs) are used for their action on the heart. or other parts of the vascular ... death is with antiplatelet agents (aspirin, clopidogrel) and lipid. lowering agents. Recently, angiotensin-converting enzyme ( ...
Cardiovascular Agents. Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. ...
Cardiovascular Effects. Terbutaline sulfate, like all other beta-adrenergic agonists, can produce a clinically significant ... Use of Anti-Inflammatory Agents. The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma ... Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as terbutaline, but may ... The concomitant use of terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the ...
Other Cardiovascular Agents. VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, ... Agents Causing Renin Release. The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin ... Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any ... Agents Increasing Serum Potassium. VASOTEC attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing ...
Agents in Medicinal Chemistry provides in-depth reviews on the development of cardiovascular drugs and hematological agents. ... Cardiovascular & Hematological Agents in Medicinal Chemistry. (Formerly as Current Medicinal Chemistry - Cardiovascular & ...
The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in ... European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). ... Cardiovascular Agents / therapeutic use * Cardiovascular Diseases / prevention & control* * Chronic Disease / prevention & ... European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the ...
5.3 Use of Anti-Inflammatory Agents 5.4 Cardiovascular Effects 5.5 Do Not Exceed Recommended Dose 5.6 Hypersensitivity ... or within 2 weeks of discontinuation of such agents, because the action of albuterol on the cardiovascular system may be ... Cardiovascular Effects [see Warnings and Precautions (5.4)] *Immediate hypersensitivity reactions [see Warnings and Precautions ... Cardiovascular effects may occur. Use with caution in patients sensitive to sympathomimetic drugs and patients with ...
Other Cardiovascular Agents. Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, ... Agents Causing Renin Release. The antihypertensive effect of enalapril maleate is augmented by antihypertensive agents that ... Nonsteroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors). In patients who are ... Agents Increasing Serum Potassium. Enalapril maleate attenuates potassium loss caused by thiazide-type diuretics. Potassium- ...
Anti-Arrhythmia Agents / therapeutic use * Arrhythmias, Cardiac / drug therapy * Arrhythmias, Cardiac / physiopathology ... High heart rate: a cardiovascular risk factor? Eur Heart J. 2006 Oct;27(20):2387-93. doi: 10.1093/eurheartj/ehl259. Epub 2006 ... 1 Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Freiburgstrasse, 3010 Bern, Switzerland. ...
Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. However, the ... Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. However, the ... Importantly, CYP epoxygenase-derived EETs are involved in the maintenance of cardiovascular homeostasis. In fact, in addition ... Importantly, CYP epoxygenase-derived EETs are involved in the maintenance of cardiovascular homeostasis. In fact, in addition ...
Statins and CVD (Cardio-Vascular Disease): Now Its Personal!. * Permalink Gallery How should artificial agents make risky ...
Polyphenols - possible therapeutic agents against cardiovascular disease. Katarzyna Goszcz, Ian L Megson, G.J. McDougall, D. ... Polyphenols - possible therapeutic agents against cardiovascular disease. / Goszcz, Katarzyna; Megson, Ian L; McDougall, G.J. ... Polyphenols - possible therapeutic agents against cardiovascular disease. Poster session presented at Society for Experimental ... Goszcz K, Megson IL, McDougall GJ, Stewart D. Polyphenols - possible therapeutic agents against cardiovascular disease. 2011. ...
Hermansen K, Mortensen LS (2007) Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug ... cardiovascular disease (CHD or stroke) and total mortality. In total, 1,922 cardiovascular-disease events occurred, based on ... Eeg-Olofsson, K., Cederholm, J., Nilsson, P.M. et al. Risk of cardiovascular disease and mortality in overweight and obese ... Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in ...
ANTIPLATELET AGENTS. Platelet activation and atherothrombosis play key roles in heart attacks, strokes, and the formation and ... Clinical update: cardio- vascular disease in diabetes mellitus. Atherosclerotic cardiovascular disease and heart failure in ... Lowering Cardiovascular Disease Risk for Patients With Diabetes October 13, 2017. Jeffrey Hamper, PharmD, BCACP ... Management of atherosclerotic cardiovascular disease risk factors in the older adult patient with diabetes. Diabetes Care. 2017 ...
  • Cardiovascular (CV) diseases are the leading cause of morbidity and mortality in diabetic patients. (hindawi.com)
  • Nanomedicinal Aspects in Cardiovascular Diseases, Nanomedicinal Approaches Towards Cardiovascular Disease (2021) 1: 6. (benthamscience.com)
  • For instance, in July 2020, Lilly and Boehringer Ingelheim International GmbH had set forth the results related with phase 3 trial of Jardiance (empagliflozin) that had supported in reducing risks of cardiovascular diseases or hospitalization for heart failure in adults with and without diseases. (researchandmarkets.com)
  • Moreover, the proper treatment was been given by physicians to patients suffering from cardiovascular diseases. (researchandmarkets.com)
  • It is one of the important drugs in order to manage cardiovascular diseases. (researchandmarkets.com)
  • Some factors that are boosting the market growth in North America are increasing pervasiveness of cardiovascular diseases along with presence of the leading players in the market. (researchandmarkets.com)
  • Lee J, Hung C, Huang C, Chen Y, Chuang P, Yu J, Ho Y. Use of the CHA2DS2-VASc Score for Risk Stratification of Hospital Admissions Among Patients With Cardiovascular Diseases Receiving a Fourth-Generation Synchronous Telehealth Program: Retrospective Cohort Study. (jmir.org)
  • Chen Y, Hung C, Huang C, Lee J, Yu J, Ho Y. The Impact of Synchronous Telehealth Services With a Digital Platform on Day-by-Day Home Blood Pressure Variability in Patients with Cardiovascular Diseases: Retrospective Cohort Study. (jmir.org)
  • Huang C, Chen Y, Hung C, Lee J, Hsu T, Wu H, Chuang P, Chen M, Ho Y. The Association Between Short-term Exposure to Ambient Air Pollution and Patient-Level Home Blood Pressure Among Patients With Chronic Cardiovascular Diseases in a Web-Based Synchronous Telehealth Care Program: Retrospective Study. (jmir.org)
  • Saifan A, Alarabyat I, Alrimawi I, Al-Nsair N. Utilizing telehealth intervention to support patients with cardiovascular diseases in Jordan: A qualitative study. (jmir.org)
  • Aetna considers the use of chelation therapy experimental and investigational in the prevention and treatment of cancer, cardiovascular disease (e.g., atherosclerotic cardiovascular disease , coronary artery disease, individuals who had a myocardial infarction), neurodegenerative diseases (e.g. (aetna.com)
  • NCDs, namely cardiovascular diseases, cancer, diabetes and chronic respiratory diseases, are largely preventable by addressing the four common modifiable risk factors - tobacco use, harmful use of alcohol, unhealthy diet and physical inactivity. (who.int)
  • It is also associated with cardiovascular diseases. (sigmaaldrich.com)
  • The ten leading work related diseases and injuries were occupational lung diseases, musculoskeletal injuries, occupational cancers, severe occupational traumatic injuries, cardiovascular diseases, reproductive disorders, neurotoxic disorders, noise induced hearing loss , dermatological conditions, and psychological disorders. (cdc.gov)
  • Cardiovascular diseases were associated with exposures to metals, dusts, and trace elements, occupational inhalants and other chemicals, noise , and psychosocial stress. (cdc.gov)
  • Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial (CAMELLIA-TIMI61 Study) of lorcaserin hydrochloride (U.S. brand name: BELVIQ®, "lorcaserin") after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. (eisai.com)
  • Although, currently, treatment has proven useful in reducing vascular events, diabetic patients continue to have a higher risk of adverse cardiovascular events compared with those in nondiabetic patients. (hindawi.com)
  • Objectives We aimed to quantify the risk of major adverse cardiovascular events (MACE) among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA) and psoriasis without known PsA compared with the general population after adjusting for traditional cardiovascular risk factors. (bmj.com)
  • Daily resveratrol consumption may help to prevent and control cardiovascular disease in overweight or obese individuals. (greenmedinfo.com)
  • European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). (nih.gov)
  • The aim of this study of type 2 diabetic patients in the Swedish National Diabetes Register was to study the associations of BMI, overweight (BMI 25-29.9 kg/m 2 ) and obesity (BMI ≥ 30 kg/m 2 ) with cardiovascular disease in type 2 diabetes, as these associations have not previously been clarified. (springer.com)
  • Patients aged 30-74 years with no previous CHD or stroke ( N = 13,087) were followed for a mean of 5.6 years until 2003 for fatal or non-fatal CHD, stroke, cardiovascular disease (CHD or stroke) and total mortality. (springer.com)
  • Adjusted hazard ratios (model 1) for CHD, cardiovascular disease and total mortality with overweight were 1.27 (95% CI 1.09-1.48), 1.24 (1.09-1.41) and 1.16 (0.94-1.45), respectively, and 1.49 (1.27-1.76), 1.44 (1.26-1.64) and 1.71 (1.36-2.14) with obesity, as compared with normal weight. (springer.com)
  • Both overweight and obesity independently increased the risk of CHD and cardiovascular disease in patients with type 2 diabetes. (springer.com)
  • Specifically, pharmacists can help to address risk factors that contribute to cardiovascular disease, such as hypertension, lipid levels, and antiplatelet agents and offer lifestyle modifications when reviewing medications and counseling their patients about this chronic health disease. (pharmacytimes.com)
  • There is a strong correlation between diabetes and cardiovascular disease (CVD), which is the leading cause of death in patients with diabetes . (pharmacytimes.com)
  • ENRICH will aim to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years old) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or who are in diverse geographic regions of the U.S. with high burden of cardiovascular disease (CVD) risk factors. (nih.gov)
  • For instance, a meta-analysis from 2010 found that patients with cardiovascular disease who were light to moderate alcohol consumers, were less likely to suffer from cardiovascular and all-cause mortality. (wikipedia.org)
  • Antiplatelet agents are effective in primary and secondary prevention of arterial thrombosis (cardiovascular events, ischaemic stroke, and peripheral arterial occlusive disease). (hindawi.com)
  • Lee J, Hung C, Huang C, Chen Y, Wu H, Chuang P, Yu J, Ho Y. The Costs and Cardiovascular Benefits in Patients With Peripheral Artery Disease From a Fourth-Generation Synchronous Telehealth Program: Retrospective Cohort Study. (jmir.org)
  • However, it is less clear if the infection is also associated with an increased risk of serious non-liver-related events, such as diabetes, cardiovascular disease, malignancies and bone complications. (aidsmap.com)
  • Bioactive polyphenols and cardiovascular disease: chemical antagonists, pharmacological agents or xenobiotics that drive an adaptive response? (uhi.ac.uk)
  • Polyphenols are widely regarded to have a wide range of health-promoting qualities, including in the sphere of cardiovascular disease. (uhi.ac.uk)
  • Dive into the research topics of 'Bioactive polyphenols and cardiovascular disease: chemical antagonists, pharmacological agents or xenobiotics that drive an adaptive response? (uhi.ac.uk)
  • People with hepatitis C are at higher risk of dying from cardiovascular disease, having a stroke, or developing other cardiovascular problems than people with similar risk factors for heart disease who do not have hepatitis C, a meta-analysis of published studies has shown. (hivandhepatitis.com)
  • Previous studies have produced inconsistent findings regarding the risk of cardiovascular disease in people with hepatitis C virus (HCV). (hivandhepatitis.com)
  • The impact of HCV on carotid plaques was not statistically significant in populations in which smoking was less common, showing that smoking exacerbates any effect of hepatitis C on the development of cardiovascular disease, unsurprisingly. (hivandhepatitis.com)
  • The authors note that even after allowing for the well-established risk factors for heart disease -- diabetes, high blood pressure, and smoking -- the risk of death, cardiovascular disease, and carotid artery disease was still elevated in people with hepatitis C. Indeed, they describe the effect of hepatitis C on cardiovascular risk as 'especially pronounced' in populations where diabetes, high blood pressure, or smoking are common. (hivandhepatitis.com)
  • The authors suggest that the metabolic abnormalities common in people with hepatitis C may provide one explanation for the increased risk, but they also point to recent evidence showing that hepatitis C promotes inflammation, which contributes to the development of cardiovascular disease. (hivandhepatitis.com)
  • IJD are associated with increased cardiovascular (CV) disease-related morbidity and mortality. (bmj.com)
  • 1 , 2 The majority of these deaths are attributed to atherosclerotic cardiovascular (CV) disease in particular. (bmj.com)
  • This Phase Ⅲb/IV clinical study, comprised of 12,000 patients, is being conducted over a 5-year period in partnership with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is intended to address the post-marketing requirement from the U.S. Food and Drug Administration to evaluate the long-term cardiovascular safety of lorcaserin. (eisai.com)
  • Pharmacological therapy to prevent myocardial infarction and death is with antiplatelet agents (aspirin, clopidogrel) and lipid lowering agents. (dulomix.com)
  • In unstable angina and non-STsegment elevation myocardial infarction, and in coronary stenting, antilipid drugs, heparin, and antiplatelet agents are recommended. (dulomix.com)
  • Outcomes included cardiovascular death, myocardial infarction, cerebrovascular accidents and the composite outcome (MACE). (bmj.com)
  • Use with caution in patients sensitive to sympathomimetic drugs and patients with cardiovascular or convulsive disorders. (nih.gov)
  • These agents are the drugs of choice. (medscape.com)
  • Pharmacokinetics of cardiovascular, central nervous system, and antimicrobial drugs / Peter G. Welling, Francis L. S. Tse. (who.int)
  • This paper reviews the role of currently available antiplatelet drugs in primary and secondary prevention of vascular events in diabetic patients and the limitations of these drugs, and it discusses the role of novel and more potent antiplatelets and of new agents currently under clinical development. (hindawi.com)
  • Available antiplatelet agents, such as cyclooxygenase-1 (COX-1) inhibitors (aspirin), ADP P2Y 12 receptor antagonists, and GP IIb/IIIa receptor inhibitors, are effective and save in the treatment and prevention of thrombotic events, these drugs interfere with the platelet activation process, including adhesion, release, and aggregation. (hindawi.com)
  • Because antiviral agents taken prophylactically may prevent illness but not subclinical infection, some persons who take these drugs may still develop immune responses that will protect them when they are exposed to antigenically related viruses in later years. (cdc.gov)
  • Cardiovascular Drugs / Antilipemic Agents / HMG-CoA Reductase Inhibitors (i.e. (tevausa.com)
  • The commentary on the trial by Marso et al 1 assessing the cardiovascular (CV) safety of a new agent for treating type 2 diabetes highlights a recognised dilemma in clinical research on CV risk in assessment of new therapeutic agents. (bmj.com)
  • Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. (frontiersin.org)
  • Large clinical trials have shown that antiplatelet agents are effective in the prevention of recurrent cardiovascular events in diabetes. (hindawi.com)
  • Dr. Julio Rosenstock spoke on the ongoing CAROLINA cardiovascular outcome trial for BI/Lilly's Tradjenta (linagliptin), which he discussed recently during a Sanofi symposium on cardiovascular considerations in diabetes - read our coverage of his full talk on CVOTs on page 4 of our EASD 2013 Day #1 Report at http://www.closeconcerns.com/knowledgebase/r/19d6b5c0 . (closeconcerns.com)
  • Using real-world data (RWD) from three U.S. claims data sets, we aim to predict the findings of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) comparing linagliptin versus glimepiride in patients with type 2 diabetes (T2D) at increased cardiovascular risk by using a novel framework that requires passing prespecified validity checks before analyzing the primary outcome. (diabetesjournals.org)
  • VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. (rxlist.com)
  • Higher consumption of fruit and vegetables is associated with a lower risk of all cause mortality, particularly cardiovascular mortality. (greenmedinfo.com)
  • A secondary aim was to analyse associations between weight changes and cardiovascular complications and total mortality. (springer.com)
  • Cardiovascular mortality was calculated from the results of 3 cohort studies which followed 68,365 people and observed 735 deaths. (hivandhepatitis.com)
  • Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. (hivandhepatitis.com)
  • Platelets have a "key role" in atherogenesis and its thrombotic complications in subjects with DM [ 3 ], and the concomitant presence of multiple "classical" cardiovascular risk factors (arterial hypertension, cigarette smoking, and hyperlipidemia) in diabetic subjects contributes to enhanced atherothrombotic risk. (hindawi.com)
  • Stroke or heart attack (cerebro-cardiovascular events). (hivandhepatitis.com)
  • The impact of hepatitis C on the incidence of cardiovascular events, including stroke, was calculated from 8 studies, combining data from 390,602 people who experienced 18,388 events. (hivandhepatitis.com)
  • Although these interactions remain to be further examined in humans, the physiological functions of taurine appear to be inconsistent with the adverse cardiovascular symptoms associated with excessive consumption of caffeine-taurine containing beverages. (researchgate.net)
  • These agents prevent recurrent or ongoing thromboembolic occlusion. (medscape.com)
  • The Center for Experimental Therapeutics works with OHSU's Knight Cancer Institute, Vollum Institute, Knight Cardiovascular Institute, Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Brenden-Colson Center, Center for Regenerative Medicine, Brain Institute, and more. (ohsu.edu)
  • It has been in use for more than 40 years and is generally an important agent for the treatment of essential hypertension. (medscape.com)
  • In the cardiovascular system, mercury induces hypertension in humans and animals that has wide-ranging consequences, including alterations in endothelial function. (hindawi.com)
  • The most prescribed agents are aspirin and clopidogrel, two cornerstones of the antiplatelet therapy [ 7 - 9 ]. (hindawi.com)
  • 4 As per the FDA guidance, in order for investigational agents to be approved they added the requirement that they demonstrate no excess increase in CV risk in large safety outcome studies. (bmj.com)
  • We registered the protocol ( NCT03648424 , ClinicalTrials.gov) before evaluating the composite cardiovascular outcome based on CAROLINA's primary end point. (diabetesjournals.org)
  • Linagliptin was associated with a 9% decreased risk in the composite cardiovascular outcome with a CI including the null (HR 0.91 [0.79-1.05]), in line with noninferiority. (diabetesjournals.org)
  • In a nonrandomized RWD study, we found that linagliptin has noninferior risk of a composite cardiovascular outcome compared with glimepiride. (diabetesjournals.org)
  • Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. (nel.edu)
  • Within Medicare and two commercial claims data sets (May 2011-September 2015), we identified a 1:1 propensity score-matched (PSM) cohort of T2D patients 40-85 years old at increased cardiovascular risk who initiated linagliptin or glimepiride by adapting eligibility criteria from CAROLINA. (diabetesjournals.org)
  • Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants: May potentiate effect of albuterol on the cardiovascular system. (nih.gov)
  • Use of simvastatin is contraindicated in medications that are strong inhibitors of cytochrome P450 activity (such as cyclosporine, ketoconazole, diltiazem, ciprofloxacin or amiodarone), and dose adjustments are appropriate for its use with other agents that inhibit CYP 3A4. (nih.gov)
  • A Totally-Encapsulating Chemical Protective (TECP) suit that protects against CBRN agents. (cdc.gov)
  • Some early reviews showed that light alcohol consumption may have a protective effect on cardiovascular health. (wikipedia.org)
  • The purpose of this document is to enable health care workers and public health officials to recognize when a chemical event has poisoned people by exposing them to vesicants/blister agents. (cdc.gov)
  • This Funding Opportunity Announcement (FOA) invites applications for clinical or community sites to be part of a multi-center group- or cluster-randomized trial under the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program. (nih.gov)
  • Aspirin is an analgesic and antipyretic agent used in the treatment of fever and pain as in arthritis. (sigmaaldrich.com)
  • Nerve agents are readily absorbed from the respiratory tract. (cdc.gov)
  • Moreover, the concomitant presence of multiple "classical" cardiovascular risk factors in diabetic subjects contributes to enhanced atherothrombotic risk. (hindawi.com)
  • The section of the book tries to highlight some of the aspects related to the exploration of nanotechnology in the case of cardiovascular treatment. (benthamscience.com)
  • However, high cost involvement in treatment along with strict governmental rules and regulation for approval of drug are some major factors constraints that are hindering the growth of the global cardiovascular drug market across the globe. (researchandmarkets.com)
  • High heart rate: a cardiovascular risk factor? (nih.gov)
  • Consumption of high flavanol dark chocolate confers modest improvements in cardiovascular function. (greenmedinfo.com)
  • Based on drug type, the market is segmented into anti-clotting agents, antihyperlipidemic, calcium channel blockers, renin-angiotensin system blockers and other. (researchandmarkets.com)
  • Most of the safety concerns have centered on the effect of energy drinks on cardiovascular and central nervous system function. (researchgate.net)
  • Vesicants, also referred to as "blister agents," were the most commonly used chemical warfare agents during World War I. The most likely routes of exposure are inhalation, dermal contact, and ocular contact. (cdc.gov)
  • G-type nerve agents (GA, GB, and GD) are clear, colorless liquids that are volatile at ambient temperatures. (cdc.gov)
  • G-type agents are clear,colorless, and tasteless liquids that are miscible in water and most organic solvents. (cdc.gov)
  • Based on the drug type, the anti-clotting agents segment holds a significant share in the market. (researchandmarkets.com)
  • However, the researchers warned against encouraging cardiovascular patients who do not regularly consume alcohol to start drinking due to lack of controlled intervention studies and evidence. (wikipedia.org)
  • Nerve agents are the most toxic of the known chemical warfare agents. (cdc.gov)
  • Coadministration with these agents may cause increases in simvastatin levels and potentiate its hepatic or muscle toxicity. (nih.gov)
  • This agent is often preferred because of its potassium-sparing effects, particularly in a clinical setting that includes secondary hyperaldosteronism. (medscape.com)